Education
About Us
Working with TipRanks
Follow Us
Icecure Medical Ltd. (ICCM)
:ICCM
ICCM Stock Chart & Stats
$0.86
-$0.06(-4.41%)
At close: 4:00 PM EST
$0.86
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$0.59 - $1.63
Previous CloseN/A
Volume318.06K
Average Volume (3M)423.15K
Market Cap
$47.15M
Enterprise Value$56.72M
Total Cash (Recent Filing)$10.01M
Total Debt (Recent Filing)$288.00K
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Mar 26, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding68,693,054
10 Day Avg. Volume298,500
30 Day Avg. Volume423,150
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)8.11
Price to Sales (P/S)17.01
P/FCF Ratio-4.43
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue19.07
Enterprise Value/Gross Profit54.38
Enterprise Value/Ebitda-3.76
Forecast
1Y Price Target
$2.75Price Target Upside219.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.21
Revenue Forecast (FY)$3.81M
Bulls Say, Bears Say
Bulls Say
FDA AuthorizationProSense's FDA marketing authorization for early-stage breast cancer is seen as a meaningful milestone that should drive revenue growth.
Market ExpansionIncreasing interest in ProSense technology across US and international markets is noted, reflecting its growing acceptance and potential.
Regulatory ApprovalThe ProSense system received regulatory approval in Switzerland for treating various tissues, which is expected to bolster its market presence.
Bears Say
Regulatory RequirementsThe FDA has requested a post-market surveillance study, requiring IceCure to conduct additional research with 400 patients at 30 sites.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $0.59 and its highest was $1.63 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $47.15M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Mar 26, 2026 which is in 108 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on Nov 19, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.01.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -0.05.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 68,693,054 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -2.778%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
Icecure Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (219.77% Upside)
$2.75 (219.77% Upside)
Hedge Fund Trend
Decreased
By 11.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.62%
12-Months-Change
Fundamentals
Return on Equity
-157.91%
Trailing 12-Months
Asset Growth
-1.31%
Trailing 12-Months
Company Description
Icecure Medical Ltd.
Icecure Medical (ICCM) is a medical device company specializing in innovative cryoablation solutions for the treatment of tumors. The company focuses on the development and commercialization of its proprietary technology, the ProSense system, which utilizes precise cryotherapy to target and destroy cancerous tissues. Operating primarily in the healthcare sector, Icecure Medical aims to enhance patient outcomes while providing minimally invasive treatment options across various types of tumors, including breast and liver cancers.
ICCM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook due to the significant milestone of FDA marketing authorization for ProSense, opening up substantial market opportunities and driving global interest. Financially, the company has improved its cash position, although revenue and gross margin have seen declines. Overall, the highlights of strategic achievements and market potential outweigh the current financial challenges.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$2.75
▲(219.77% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.12% Other Institutional Investors
99.82% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---